ArticleBMC endocrine disorders2025
Progressive hypergonadotropic hypogonadism in an adolescent with 22q11.2 deletion syndrome.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiGeorge syndrome is a common microdeletion disorder caused by deletion in the 22q11.2 region. It typically presents with immune dysfunction, parathyroid hypoplasia, and congenital heart defects. Testis-specific serine/threonine kinases (TSSKs), involved in spermatogenesis, are located in this region. Although reproductive issues like hypogonadism and infertility have been reported, progressive hypergonadotropic hypogonadism has not previously been described in patients with DiGeorge syndrome. CASE PRESENTATION: : We report a 19-year-old male diagnosed with DiGeorge syndrome at age 13, who exhibited pubertal arrest. At age 15, his testicular volumes were 5 mL (right) and 6 mL (left). Gonadotropin levels were elevated (FSH and LH), but testosterone was adequate, so treatment was deferred. By age 19, the clinical findings remained unchanged. Despite planning for semen analysis, the patient reported limited erections and no ejaculation, preventing assessment. This represents the first reported case of progressive hypergonadotropic hypogonadism in DiGeorge syndrome.
conclusionsThis case expands the endocrine phenotype of DiGeorge syndrome and underscores the importance of regular pubertal assessments. When pubertal delay is suspected, timely hormonal and genetic evaluation is crucial to detect rare but significant complications such as primary gonadal failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.